Scholars@Duke
Gowthami Morey Arepally

Gowthami Morey Arepally

Professor of Medicine
Medicine, Hematology
Duke Box 3486, Durham, NC 27710
Rm 356A Sands Bldg, Research Drive, Durham, NC 27710

Featured Works

Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results.

Journal article J Thromb Thrombolysis · August 2008 Featured Publication PURPOSE: We determined the seroprevalence of platelet factor 4 (PF4)/heparin antibodies in healthy subjects. METHODS: A literature search identified studies in which healthy subjects were evaluated using commercial immunoassays for PF4/heparin antibody (Ig ... Full text Link to item Cite

Determinants of PF4/heparin immunogenicity.

Journal article Blood · December 15, 2007 Featured Publication Heparin-induced thrombocytopenia (HIT) is an antibody-mediated disorder that occurs with variable frequency in patients exposed to heparin. HIT antibodies preferentially recognize large macromolecular complexes formed between PF4 and heparin over a narrow ... Full text Link to item Cite

Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly.

Journal article J Clin Apher · February 2007 Featured Publication Heparin-induced thrombocytopenia (HIT) is the most common drug-induced, antibody-mediated cause of thrombocytopenia and thrombosis. HIT is caused by IgG antibodies that bind to epitopes on platelet factor 4 (PF4) released from activated platelets that deve ... Full text Link to item Cite

PF4/heparin complexes are T cell-dependent antigens.

Journal article Blood · August 1, 2005 Featured Publication Heparin-induced thrombocytopenia (HIT) is a life-threatening, thrombotic disorder associated with development of anti-platelet factor 4 (anti-PF4)/heparin autoantibodies. Little is known about the antigenic and cellular requirements that initiate the immun ... Full text Link to item Cite